中国神经再生研究(英文版) ›› 2017, Vol. 12 ›› Issue (2): 242-249.doi: 10.4103/1673-5374.199011

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

蛋白酶活化受体1拮抗剂对窒息性心脏骤停致全脑缺血再灌注损伤的保护

  

  • 收稿日期:2016-12-16 出版日期:2017-02-15 发布日期:2017-02-15
  • 基金资助:

    湖北省自然科学基金项目(2010CDB09101)

A protease-activated receptor 1 antagonist protects against global cerebral ischemia/reperfusion injury after asphyxial cardiac arrest in rabbits

Jing-ning Yang1, 2, Jun Chen2, Min Xiao1   

  1. 1 Department of Emergency Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China; 
    2 Department of Immunology, Hubei University of Medicine, Shiyan, Hubei Province, China
  • Received:2016-12-16 Online:2017-02-15 Published:2017-02-15
  • Contact: Min Xiao, M.D., xiaomin6210@126.com.
  • Supported by:

    This study was supported by the Natural Science Foundation of Hubei Province of China, No. 2010CDB09101.

摘要:

脑缺血再灌注损伤可诱导凝血酶产生,通过蛋白酶活化受体1诱导脑损伤,但其作用机制还不明确。实验利用窒息性心脏骤停方法建立日本大耳白兔短暂性全脑缺血再灌注损伤模型,10min后静脉注射25 μg/kg蛋白酶活化受体1拮抗剂SCH79797,48h后见兔血清神经元特异性烯醇化酶水平降低,神经功能障碍明显减轻,海马细胞凋亡减少,ERK磷酸化水平增加,c-Jun水平下降,中性粒细胞浸润减少;而在SCH79797干预前10min时静脉注射3 mg/kg磷脂酰肌醇3-激酶/Akt抑制剂LY29004,可抑制上述变化。结果表明,SCH79797通过ERK、JNK/c-jun和PI3K/Akt信号通路发挥抗炎和抗神经元凋亡作用,进而减轻脑神经元的损伤。

ORCID:0000-0002-9439-4308(Min Xiao)

关键词: 神经再生, 蛋白酶激活受体1 , 全脑缺血再灌注, 心脏骤停, 神经保护, SCH79797 , 细胞凋亡, 炎症, 神经元特异性烯醇化酶, 海马

Abstract:

Cerebral ischemia/reperfusion injury is partially mediated by thrombin, which causes brain damage through protease-activated receptor 1 (PAR1). However, the role and mechanisms underlying the effects of PAR1 activation require further elucidation. Therefore, the present study investigated the effects of the PAR1 antagonist SCH79797 in a rabbit model of global cerebral ischemia induced by cardiac arrest. SCH79797 was intravenously administered 10 minutes after the model was established. Forty-eight hours later, compared with those administered saline, rabbits receiving SCH79797 showed markedly decreased neuronal damage as assessed by serum neuron specific enolase levels and less neurological dysfunction as determined using cerebral performance category scores. Additionally, in the hippocampus, cell apoptosis, polymorphonuclear cell infiltration, and c-Jun levels were decreased, whereas extracellular signal-regulated kinase phosphorylation levels were increased. All of these changes were inhibited by the intravenous administration of the phosphoinositide 3-kinase/Akt pathway inhibitor LY29004 (3 mg/kg) 10 minutes before the SCH79797 intervention. These findings suggest that SCH79797 mitigates brain injury via anti-inflammatory and anti-apoptotic effects, possibly by modulating the extracellular signal-regulated kinase, c-Jun N-terminal kinase/c-Jun and phosphoinositide 3-kinase/Akt pathways.

Key words: nerve regeneration, protease-activated receptor 1, global cerebral ischemia/reperfusion, cardiac arrest, neuroprotection, SCH79797, apoptosis, inflammation, neuron specific enolase, hippocampus, neural regeneration